drugset / Trial / NCT04944017
Ketamine for the Treatment of Depression in Parkinson's Disease
Phase 2
Completed
51 enrolled
Yale University
Michael J. Fox Foundation for Parkinson's Research · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
Timeline
- Start
- 2021-11-23
- Primary completion
- 2025-09-24
- Completion
- 2025-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |